Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611083 | 0.98 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TSHRKDM4ESIGMAR1 | |
| SCHEMBL2861071 | 0.93 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TSHRKDM4ESIGMAR1 | |
| SCHEMBL22236675 | 0.93 | KDM4E (0.46) | KDM4ESIGMAR1EPHX1EPHX2LMNA | |
| SCHEMBL20794221 | 0.88 | ALDH1A1 (0.53) | ALDH1A1CYP3A4TSHRKDM4ESIGMAR1 | |
| SCHEMBL11592853 | 0.87 | ALDH1A1 (0.46) | ALDH1A1CYP3A4TSHRKDM4ESIGMAR1 | |
| SCHEMBL11057062 | 0.86 | KDM4E (0.48) | ALDH1A1CYP3A4TSHRKDM4EEPHX1 | |
| SCHEMBL15203118 | 0.84 | ALDH1A1 (0.57) | ALDH1A1CYP3A4TSHRKDM4EGNAI3 | |
| SCHEMBL7608632 | 0.83 | KDM4E (0.46) | ALDH1A1CYP3A4TSHRKDM4ESIGMAR1 | |
| SCHEMBL5138440 | 0.82 | GNAI3 (0.54) | ALDH1A1CYP3A4TSHRSIGMAR1EPHX1 | |
| SCHEMBL11052987 | 0.82 | KDM4E (0.56) | ALDH1A1TSHRKDM4EEPHX1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CYP3A4 2542/4885TSHR 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.